Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib + Sacituzumab Tirumotecan in ALK+ NSCLC
NCT07750704Phase 2Not yet recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07750704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07750704.